NCT04600999

Clinical Trial of Favipiravir Treatment of Patients With COVID-19

An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: University of Pecs · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint.

Conditions

• SARS-CoV-2 Infection

Interventions

Type	Name	Description
DRUG	Favipiravir	Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]

Timeline

• Start date: 2020-10-07
• Primary completion: 2020-12-28
• Completion: 2020-12-28
• First posted: 2020-10-23
• Last updated: 2022-11-01

Locations

5 sites across 1 country: Hungary